Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

GDF15 antibody (C-Term) (Biotin)

GDF15 Reactivity: Human, Mouse WB, ELISA Host: Rabbit Polyclonal Biotin
Catalog No. ABIN1043920
  • Target See all GDF15 Antibodies
    GDF15 (Growth Differentiation Factor 15 (GDF15))
    Binding Specificity
    • 18
    • 15
    • 10
    • 8
    • 8
    • 6
    • 5
    • 5
    • 3
    • 3
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    C-Term
    Reactivity
    • 90
    • 29
    • 23
    • 1
    • 1
    Human, Mouse
    Host
    • 87
    • 12
    • 3
    • 1
    Rabbit
    Clonality
    • 87
    • 15
    • 1
    Polyclonal
    Conjugate
    • 53
    • 14
    • 9
    • 8
    • 3
    • 3
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    This GDF15 antibody is conjugated to Biotin
    Application
    • 88
    • 55
    • 37
    • 17
    • 13
    • 13
    • 9
    • 7
    • 6
    • 5
    • 3
    • 3
    • 2
    • 1
    • 1
    Western Blotting (WB), ELISA
    Specificity
    Nag-1 Antibody Biotin Conjugated antibody was affinity purified from monospecific antiserum by immunoaffinity chromatography.  This antibody reacts with the C-terminus of endogenous NAG-1 protein from human and mouse tissues.  A BLAST analysis suggests reactivity with NAG-1 from chimpanzee and macaque based on a 100% homology. Partial reactivity is expected against rat based on an 86% homology with the immunizing sequence.  Cross-reactivity with NAG-1 from other sources has not been determined.
    Characteristics
    Non-steroidal anti-inflammatory drug (NSAID) activated gene (NAG-1) is a member of the transforming growth factor-beta (TGF-beta) superfamily. NAG-1 is also known as Macrophage Inhibitory Cytokine-1 (MIC-1), Growth Differentiation Factor 15 (GDF15), Placental Bone Morphogenetic Protein (PLAB), or Prostate Derived Factor (PDF). NAG-1 is expressed in human placenta, prostate and colon. It possesses antitumorigenic and proapoptotic activities. NAG-1 expression is dramatically increased in inflammation, injury and malignancy. Increase of NAG-1 expression is a feature of many cancers including breast, colon, pancreas and prostate. In a number of studies, NAG-1 expression was increased by a number of NSAIDs. This increase in expression may correlate with the chemopreventive effect NSAIDs seem to have with certain cancers. NAG-1 expression is also induced by PPAR gamma ligands and by several dietary compounds such as conjugated linoleic acids (CLAs), naturally occurring fatty acids in ruminant food products, indoles, epicatechin gallate, and genistein. Induced expression of NAG-1 results in stimulation of apoptosis and inhibition of cell growth. Inhibition of NAG-1 induced expression by small interference RNA (siRNA) results in repression of induced apoptosis. NAG-1 expression is regulated by a numbers of transcription factors such as ERG-1 and Sp1. EGR-1 may be necessary for NSAID-induced NAG-1 expression. The study of expression of NAG-1 proteins, including variants, is important to define their potential role as serum biomarkers for cancer diagnosis, treatment monitoring, epidemiology study, and nutrition surveys.
    Immunogen
    Nag-1 Antibody Biotin Conjugated antibody was prepared by repeated immunizations with a synthetic peptide corresponding to a region near the carboxy terminal end of human NAG-1 protein.  A residue of cysteine was added to facilitate coupling to KLH.
    Immunogen Type: Peptide
    Isotype
    IgG
  • Application Notes
    Nag-1 Antibody Biotin Conjugated antibody is suitable for ELISA and western blotting of human and mouse NAG-1 protein.  For detection of NAG-1 in human serum, a sandwich ELISA is suggested using this antibody in combination with anti-NAG-1/GDF15 (N-terminal), H variant or D variant specific antibodies.  Specific conditions for reactivity should be optimized by the end user.  Expect bands in Western blots of approximately 14 and 28 kDa in size corresponding to NAG-1 monomer and dimer, respectively, using the appropriate cell lysate or extract.
    Comment

    Gene Name: GDF15

    Restrictions
    For Research Use only
  • Format
    Lyophilized
    Reconstitution
    Reconstitution Buffer: Restore with deionized water (or equivalent), Reconstitution Volume: 100 µL
    Concentration
    1.0 mg/mL
    Buffer
    0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2, 10 mg/mL Bovine Serum Albumin (BSA) - Immunoglobulin and Protease free
    Preservative
    Sodium azide
    Precaution of Use
    This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Storage
    4 °C/-20 °C
    Storage Comment
    Store vial at 4 °C prior to restoration. For extended storage aliquot contents and freeze at -20 °C or below. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. This product is stable for several weeks at 4 °C as an undiluted liquid. Dilute only prior to immediate use. Expiration date is one (1) year from date of opening.
    Expiry Date
    12 months
  • Baek, Eling: "Changes in gene expression contribute to cancer prevention by COX inhibitors." in: Progress in lipid research, Vol. 45, Issue 1, pp. 1-16, (2006) (PubMed).

  • Target
    GDF15 (Growth Differentiation Factor 15 (GDF15))
    Alternative Name
    Nag-1 (GDF15 Products)
    Synonyms
    GDF15 antibody, GDF-15 antibody, MIC-1 antibody, MIC1 antibody, NAG-1 antibody, PDF antibody, PLAB antibody, PTGFB antibody, SBF antibody, growth differentiation factor 15 antibody, GDF15 antibody, Gdf15 antibody
    Background
    Non-steroidal anti-inflammatory drug (NSAID) activated gene (NAG-1) is a member of the transforming growth factor-beta (TGF-beta) superfamily. NAG-1 is also known as Macrophage Inhibitory Cytokine-1 (MIC-1), Growth Differentiation Factor 15 (GDF15), Placental Bone Morphogenetic Protein (PLAB), or Prostate Derived Factor (PDF). NAG-1 is expressed in human placenta, prostate and colon. It possesses antitumorigenic and proapoptotic activities. NAG-1 expression is dramatically increased in inflammation, injury and malignancy. Increase of NAG-1 expression is a feature of many cancers including breast, colon, pancreas and prostate. In a number of studies, NAG-1 expression was increased by a number of NSAIDs. This increase in expression may correlate with the chemopreventive effect NSAIDs seem to have with certain cancers. NAG-1 expression is also induced by PPAR gamma ligands and by several dietary compounds such as conjugated linoleic acids (CLAs), naturally occurring fatty acids in ruminant food products, indoles, epicatechin gallate, and genistein. Induced expression of NAG-1 results in stimulation of apoptosis and inhibition of cell growth. Inhibition of NAG-1 induced expression by small interference RNA (siRNA) results in repression of induced apoptosis. NAG-1 expression is regulated by a numbers of transcription factors such as ERG-1 and Sp1. EGR-1 may be necessary for NSAID-induced NAG-1 expression. The study of expression of NAG-1 proteins, including variants, is important to define their potential role as serum biomarkers for cancer diagnosis, treatment monitoring, epidemiology study, and nutrition surveys.
    Synonyms: NAG-1, GDF15, MIC-1, nonsteroidal anti-inflammatory drug-activated gene, NSAID-activated gene 1 protein, growth differentiation factor 15, macrophage inhibitory compound 1, prostate-derived factor
    Gene ID
    9518
    UniProt
    Q99988
    Pathways
    SARS-CoV-2 Protein Interactome
You are here:
Support